{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:29:02Z","timestamp":1784298542241,"version":"3.55.0"},"reference-count":185,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.prp.2025.156308","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:02:32Z","timestamp":1764172952000},"page":"156308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Progress in nanotechnology-based strategies to enhance tamoxifen therapy for breast cancer management"],"prefix":"10.1016","volume":"277","author":[{"given":"Karthik","family":"Mangu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashna Nimish","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1394-7298","authenticated-orcid":false,"given":"Md.","family":"Rizwanullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.156308_bib1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2025.156308_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2025.156308_bib3","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.prp.2025.156308_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2025.156308_bib5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41416-023-02451-3","article-title":"Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence","volume":"129","author":"Makhlouf","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib6","doi-asserted-by":"crossref","DOI":"10.3788\/COL202018.051701","article-title":"Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure","volume":"18","author":"Ma","year":"2020","journal-title":"Chin. Opt. Lett."},{"key":"10.1016\/j.prp.2025.156308_bib7","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1111\/febs.16768","article-title":"MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone-mediated autophagy","volume":"290","author":"Zhou","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.prp.2025.156308_bib8","doi-asserted-by":"crossref","first-page":"9834","DOI":"10.3390\/ijerph18189834","article-title":"Estrogen-receptor-positive breast cancer in postmenopausal women: the role of body composition and physical exercise","volume":"18","author":"Dimauro","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.prp.2025.156308_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jsbmb.2019.03.002","article-title":"Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression","volume":"189","author":"Bhardwaj","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.prp.2025.156308_bib10","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.3390\/ijms24076834","article-title":"A basic review on estrogen receptor signaling pathways in breast cancer","volume":"24","author":"Clusan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib11","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.2174\/0929867329666221006110528","article-title":"Effectiveness of selective estrogen receptor modulators in breast cancer therapy: An update","volume":"30","author":"Das","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prp.2025.156308_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12609-014-0144-1","article-title":"Advances in preventive therapy for estrogen-receptor-negative breast cancer","volume":"6","author":"Litzenburger","year":"2014","journal-title":"Curr. Breast Cancer Rep."},{"key":"10.1016\/j.prp.2025.156308_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejmech.2017.11.056","article-title":"Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives","volume":"143","author":"Shagufta","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.prp.2025.156308_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-14-0448","article-title":"The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer","volume":"22","author":"Jordan","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib15","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.3390\/pharmaceutics15102373","article-title":"Tamoxifen-loaded eudragit nanoparticles: Quality by design approach for optimization of nanoparticles as delivery system","volume":"15","author":"Khattak","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156308_bib16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/liv.14434","article-title":"Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"40","author":"Lee","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.prp.2025.156308_bib17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3892\/ol.2015.2962","article-title":"Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)","volume":"9","author":"Hu","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2025.156308_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108801","article-title":"From physiology to pathology: Emerging roles of GPER in cardiovascular disease","volume":"267","author":"Wang","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2025.156308_bib19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/ijms22020525","article-title":"Estrogen receptors: Therapeutic perspectives for the treatment of cardiac dysfunction after myocardial infarction","volume":"22","author":"da Silva","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.2174\/1381612826666200318170716","article-title":"Nanomedicines in diagnosis and treatment of cancer: An update","volume":"26","author":"Haider","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.prp.2025.156308_bib21","article-title":"Harnessing natural polysaccharides-based nanoparticles for oral delivery of phytochemicals: knocking down the barriers","volume":"82","author":"Afzal","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib22","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.3390\/polym13224036","article-title":"Recent advancement in chitosan-based nanoparticles for improved oral bioavailability and bioactivity of phytochemicals: challenges and perspectives","volume":"13","author":"Imam","year":"2021","journal-title":"Polymers"},{"key":"10.1016\/j.prp.2025.156308_bib23","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ac1098","article-title":"Exemestane encapsulated polymer-lipid hybrid nanoparticles for improved efficacy against breast cancer: optimization, in vitro characterization and cell culture studies","volume":"32","author":"Rizwanullah","year":"2021","journal-title":"Nanotechnology"},{"key":"10.1016\/j.prp.2025.156308_bib24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2017.00620","article-title":"Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation","volume":"8","author":"Quirke","year":"2017","journal-title":"Front. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.847113","article-title":"Interactions between natural products and tamoxifen in breast cancer: a comprehensive literature review","volume":"13","author":"Yen","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1530\/ERC-14-0092","article-title":"Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer","volume":"21","author":"Jordan","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2010.32.2933","article-title":"Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer","volume":"29","author":"Hackshaw","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156308_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41416-023-02158-5","article-title":"Tamoxifen evolution","volume":"128","author":"Howell","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib29","first-page":"29","article-title":"Tamoxifen for women at high risk of breast cancer","volume":"6","author":"Nazarali","year":"2014","journal-title":"Breast Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/17512433.2019.1610390","article-title":"Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen","volume":"12","author":"Sanchez-Spitman","year":"2019","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/sj.ijo.0801488","article-title":"Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer","volume":"25","author":"Nguyen","year":"2001","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.prp.2025.156308_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ctrv.2015.01.002","article-title":"Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping","volume":"41","author":"Binkhorst","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2025.156308_bib33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.steroids.2007.07.009","article-title":"New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer","volume":"72","author":"Jordan","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.prp.2025.156308_bib34","article-title":"Evaluation the potential of \u03b3-cyclodextrin metal-organic frameworks in enhancing tamoxifen citrate solubility and permeability focusing on particle size","volume":"104","author":"Mutlu-A\u011fardan","year":"2025","journal-title":"J. Drug Deliv. Sci. Tech."},{"key":"10.1016\/j.prp.2025.156308_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fphar.2012.00092","article-title":"Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance","volume":"3","author":"Dickschen","year":"2012","journal-title":"Front. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/clpt.2011.153","article-title":"Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score","volume":"90","author":"Barginear","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.prp.2025.156308_bib37","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","article-title":"Clinical and biomarker predictors of side effects from tamoxifen","volume":"132","author":"Lorizio","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2025.156308_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41416-018-0369-2","article-title":"Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis","volume":"120","author":"Eggemann","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.6026\/97320630012135","article-title":"Molecular mechanisms and mode of tamoxifen resistance in breast cancer","volume":"12","author":"Ali","year":"2016","journal-title":"Bioinformation"},{"key":"10.1016\/j.prp.2025.156308_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.592912","article-title":"Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer","volume":"11","author":"Yao","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib41","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/s41467-025-61112-6","article-title":"Small-molecule-induced liquid-liquid phase separation suppresses the carcinogenesis of \u03b2-catenin","volume":"16","author":"Yan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2025.156308_bib42","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cac2.70048","article-title":"Short-chain acyl post-translational modifications in cancers: mechanisms, roles, and therapeutic implications","volume":"45","author":"Wu","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.prp.2025.156308_bib43","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ijpharm.2013.03.036","article-title":"Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies","volume":"454","author":"Shete","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2020.114534","article-title":"Cationic self-nanoemulsifying formulations of tamoxifen with improved biopharmaceutical attributes and anticancer activity: Systematic development and evaluation","volume":"320","author":"Shi","year":"2020","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.prp.2025.156308_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/09603271251322531","article-title":"Enhancing breast cancer treatment: Evaluating the efficacy of hyaluronic acid-coated tamoxifen-loaded solid lipid nanoparticles on MCF7 cells","volume":"44","author":"Ghayoumipour","year":"2025","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.prp.2025.156308_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1166\/jnn.2016.10651","article-title":"Development of novel polymer-lipid hybrid nanoparticles of tamoxifen: In vitro and in vivo evaluation","volume":"16","author":"Varthya","year":"2016","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.prp.2025.156308_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejps.2018.04.040","article-title":"Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer","volume":"120","author":"Eskiler","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fchem.2018.00360","article-title":"Nanomedicine: principles, properties, and regulatory issues","volume":"6","author":"Soares","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.prp.2025.156308_bib49","article-title":"Targeting the lung tumor microenvironment by phytochemicals and their nanoformulations","volume":"264","author":"Obaidur Rab","year":"2024","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2025.156308_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","article-title":"Oral delivery of anticancer drugs: challenges and opportunities","volume":"170","author":"Thanki","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2025.156308_bib51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/1061186X.2017.1408115","article-title":"Phytochemical based nanomedicines against cancer: current status and future prospects","volume":"26","author":"Rizwanullah","year":"2018","journal-title":"J. Drug Target"},{"key":"10.1016\/j.prp.2025.156308_bib52","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.prp.2025.156308_bib53","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/pharmaceutics13122039","article-title":"Receptor-mediated targeted delivery of surface-modified nanomedicine in breast cancer: Recent update and challenges","volume":"13","author":"Rizwanullah","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156308_bib54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molmed.2015.01.001","article-title":"Cancer nanomedicine: from targeted delivery to combination therapy","volume":"21","author":"Xu","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.prp.2025.156308_bib55","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.2147\/IJN.S459710","article-title":"Smart nanoplatforms responding to the tumor microenvironment for precise drug delivery in cancer therapy","volume":"19","author":"Wang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.prp.2025.156308_bib56","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3390\/molecules27196608","article-title":"Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: a review","volume":"27","author":"Mir","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2025.156308_bib57","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.drudis.2012.05.010","article-title":"Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy","volume":"17","author":"Parhi","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.prp.2025.156308_bib58","article-title":"Nanoparticle drug delivery systems for synergistic delivery of tumor therapy","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.prp.2025.156308_bib60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/HP.S133231","article-title":"A review of the development of tumor vasculature and its effects on the tumor microenvironment","volume":"5","author":"Forster","year":"2017","journal-title":"Hypoxia"},{"key":"10.1016\/j.prp.2025.156308_bib61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phrs.2010.03.005","article-title":"Targeting nanoparticles to cancer","volume":"62","author":"Wang","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2025.156308_bib62","first-page":"1","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"10.1016\/j.prp.2025.156308_bib63","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/acs.bioconjchem.9b00448","article-title":"Nanoparticle interactions with the tumor microenvironment","volume":"30","author":"Huai","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.prp.2025.156308_bib64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2025.156308_bib65","article-title":"Unlocking the potential: Receptor-mediated targeted drug delivery in cancer therapy","volume":"270","author":"Palanisamy","year":"2025","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2025.156308_bib66","article-title":"Current status and prospects for improved targeted delivery approaches for cancer","volume":"253","author":"Mansouri","year":"2024","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2025.156308_bib67","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","article-title":"Precision cancer nanotherapy: Evolving role of multifunctional nanoparticles for cancer active targeting","volume":"62","author":"Ahmad","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2025.156308_bib68","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/molecules25051182","article-title":"Novel tamoxifen nanoformulations for improving breast cancer treatment: Old wine in new bottles","volume":"25","author":"Day","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2025.156308_bib69","article-title":"Overcoming drug resistance with specific nano scales to targeted therapy: focused on metastatic cancers","volume":"255","author":"Kadhum","year":"2024","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2025.156308_bib70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-025-02368-w","article-title":"Nanomedicine in cancer therapeutics: Current perspectives from bench to bedside","volume":"24","author":"Abdullah","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-025-00602-1","article-title":"Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects","volume":"14","author":"Cheng","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.prp.2025.156308_bib72","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1039\/c3tb20990c","article-title":"Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics","volume":"1","author":"Mussi","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.prp.2025.156308_bib73","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/nano9040638","article-title":"Lipid-based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garc\u00eda-Pinel","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib74","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.37349\/etat.2024.00272","article-title":"Exploring the therapeutic potential of lipid-based nanoparticles in the management of oral squamous cell carcinoma","volume":"5","author":"Chaudhary","year":"2024","journal-title":"Explor. Target Antitumor Ther."},{"key":"10.1016\/j.prp.2025.156308_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1296091","article-title":"Lipid-based nanoparticles as drug delivery carriers for cancer therapy","volume":"14","author":"Waheed","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.156308_bib76","doi-asserted-by":"crossref","first-page":"13248","DOI":"10.1039\/C5CC04643B","article-title":"Multifunctional nanoparticles: recent progress in cancer therapeutics","volume":"51","author":"Raju","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.prp.2025.156308_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.prp.2025.156308_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib79","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/nnm-2019-0308","article-title":"Updates on the use of liposomes for active tumor targeting in cancer therapy","volume":"15","author":"Yan","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2025.156308_bib80","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3390\/ijms24032643","article-title":"Liposomes for tumor targeted therapy: A review","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib81","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.3390\/ijms24076615","article-title":"Liposomes in cancer therapy: How did we start and where are we now","volume":"24","author":"Fulton","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib82","article-title":"Tamoxifen\/raloxifene loaded liposomes for oral treatment of breast cancer","volume":"57","author":"A\u011fardan","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","article-title":"Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery","volume":"6","author":"Ganesan","year":"2017","journal-title":"Sustain. Chem. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib84","doi-asserted-by":"crossref","DOI":"10.1515\/ntrev-2022-0517","article-title":"Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers\u2019 development","volume":"12","author":"Mohammed","year":"2023","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.prp.2025.156308_bib85","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/08982104.2023.2268711","article-title":"Solid lipid nanoparticles: a versatile approach for controlled release and targeted drug delivery","volume":"34","author":"Munir","year":"2024","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.prp.2025.156308_bib86","article-title":"Solid lipid nanoparticles: An effective lipid-based technology for cancer treatment","volume":"86","author":"Akanda","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib87","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.3390\/ijms24076199","article-title":"Solid lipid nanoparticles: Applications and prospects in cancer treatment","volume":"24","author":"Sivadasan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib88","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3109\/10837450.2013.836218","article-title":"In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate","volume":"19","author":"Hashem","year":"2014","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib89","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1567201812666150817124133","article-title":"Nanostructured lipid carriers: A novel platform for chemotherapeutics","volume":"13","author":"Rizwanullah","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.prp.2025.156308_bib91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/2405461507666220221094925","article-title":"Nanostructured lipid carriers: A promising carrier in targeted drug delivery system","volume":"8","author":"Palaria","year":"2023","journal-title":"Curr. Nanomat"},{"key":"10.1016\/j.prp.2025.156308_bib92","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/pharmaceutics12030288","article-title":"Nanostructured lipid carriers for delivery of chemotherapeutics: A review","volume":"12","author":"Haider","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156308_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125687","article-title":"Exploring the therapeutic potential of ligand-decorated nanostructured lipid carriers for targeted solid tumor therapy","volume":"678","author":"Naz","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib94","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.colsurfb.2013.08.009","article-title":"Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity","volume":"112","author":"How","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2025.156308_bib95","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1049\/iet-nbt.2019.0276","article-title":"Development of tamoxifen-loaded surface-modified nanostructured lipid carrier using experimental design: in vitro and ex vivo characterisation","volume":"14","author":"Poovi","year":"2020","journal-title":"IET Nanobiotechnol"},{"key":"10.1016\/j.prp.2025.156308_bib96","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2174\/1381612826666200317140600","article-title":"Therapeutic nanoemulsion: Concept to delivery","volume":"26","author":"Barkat","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.prp.2025.156308_bib97","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/nano9060821","article-title":"Current applications of nanoemulsions in cancer therapeutics","volume":"9","author":"S\u00e1nchez-L\u00f3pez","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib98","article-title":"A judicious review on the applications of chemotherapeutic loaded nanoemulsions in cancer management","volume":"68","author":"Alshahrani","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib99","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/mp700091j","article-title":"A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line","volume":"5","author":"Tagne","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib100","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/pharmaceutics12121194","article-title":"Self-nano-emulsifying drug-delivery systems: From the development to the current applications and challenges in oral drug delivery","volume":"12","author":"Buya","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156308_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2020.114774","article-title":"Design of absorption enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for curcumin improved anti-cancer activity and oral bioavailability","volume":"324","author":"Kanwal","year":"2021","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.prp.2025.156308_bib102","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2217\/nnm-2017-0354","article-title":"Self-emulsifying drug-delivery systems modulate P-glycoprotein activity: role of excipients and formulation aspects","volume":"13","author":"AboulFotouh","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2025.156308_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114044","article-title":"Comparison of two self-nanoemulsifying drug delivery systems using different solidification techniques for enhanced solubility and oral bioavailability of poorly water-soluble celecoxib","volume":"241","author":"Woo","year":"2024","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2025.156308_bib104","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijbiomac.2020.02.275","article-title":"Formulation and evaluation of hyaluronic acid-based mucoadhesive self nanoemulsifying drug delivery system (SNEDDS) of tamoxifen for targeting breast cancer","volume":"152","author":"Batool","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2025.156308_bib105","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.2147\/IJN.S527023","article-title":"Polymer nanoparticles advancements for gynecological cancers","volume":"20","author":"Lin","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.prp.2025.156308_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable polymeric nanoparticles for drug delivery to solid tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib107","first-page":"467","article-title":"Targeted therapy using nanotechnology: Focus on cancer","volume":"9","author":"Sanna","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.prp.2025.156308_bib108","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.colsurfb.2015.07.013","article-title":"Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy","volume":"135","author":"Sun","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2025.156308_bib109","doi-asserted-by":"crossref","first-page":"31117","DOI":"10.34172\/bi.31117","article-title":"Recent advancement in polymeric nanoparticles for oral chemotherapy: Transforming cancer treatment","volume":"15","author":"Mangu","year":"2025","journal-title":"Bioimpacts"},{"key":"10.1016\/j.prp.2025.156308_bib110","first-page":"1001","article-title":"Polymeric nanoparticles for targeted treatment in oncology: current insights","author":"Prabhu","year":"2015","journal-title":"Int. J. Nanomed. 10"},{"key":"10.1016\/j.prp.2025.156308_bib111","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.biomaterials.2010.09.037","article-title":"The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen","volume":"32","author":"Jain","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib112","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijbiomac.2014.08.012","article-title":"Therapeutic efficacy and toxicity of tamoxifen loaded PLA nanoparticles for breast cancer","volume":"72","author":"Pandey","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2025.156308_bib113","first-page":"3107","article-title":"Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy","volume":"9","author":"Maji","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.prp.2025.156308_bib114","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejps.2015.12.031","article-title":"Recent advances in polymeric micelles for anti-cancer drug delivery","volume":"83","author":"Biswas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4155\/tde-2020-0008","article-title":"Polymeric micelles for anticancer drug delivery","volume":"11","author":"Majumder","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.prp.2025.156308_bib116","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2011.12.012","article-title":"Polymeric micelles drug delivery system in oncology","volume":"159","author":"Gong","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2025.156308_bib117","article-title":"Polymeric micelles: A novel drug delivery system for the treatment of breast cancer","volume":"77","author":"Chaudhuri","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib118","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1208\/s12249-020-01850-6","article-title":"In vitro cytotoxicity and cellular uptake of tamoxifen citrate-loaded polymeric micelles","volume":"21","author":"Nasr","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.prp.2025.156308_bib119","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s13346-023-01443-3","article-title":"Folic acid grafted mixed polymeric micelles as a targeted delivery strategy for tamoxifen citrate in treatment of breast cancer","volume":"14","author":"Nasr","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.prp.2025.156308_bib120","first-page":"136","article-title":"Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis","author":"Mignani","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.prp.2025.156308_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118814","article-title":"Dendrimers in the context of nanomedicine","volume":"573","author":"Dias","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105890","article-title":"Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer","volume":"164","author":"Dubey","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.prp.2025.156308_bib123","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1021\/acsabm.5c00498","article-title":"Emerging trends in designing the dendrimer-based drug delivery for antineoplastic therapies","volume":"8","author":"Raza","year":"2025","journal-title":"ACS Appl. Bio. Mater."},{"key":"10.1016\/j.prp.2025.156308_bib124","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.drudis.2016.09.013","article-title":"Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery","volume":"22","author":"Sharma","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.prp.2025.156308_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2020.109546","article-title":"Recent advances in dendrimer-based nanoplatform for cancer treatment: A review","volume":"126","author":"Ambekar","year":"2020","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.prp.2025.156308_bib126","doi-asserted-by":"crossref","first-page":"24808","DOI":"10.1039\/C6RA02391F","article-title":"Hydrophobic myristic acid modified PAMAM dendrimers augment the delivery of tamoxifen to breast cancer cells","volume":"6","author":"Matai","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.prp.2025.156308_bib127","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijpharm.2009.10.018","article-title":"Polymer-based nanocapsules for drug delivery","volume":"385","author":"Mora-Huertas","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib128","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/wnan.1334","article-title":"Improving drug biological effects by encapsulation into polymeric nanocapsules","volume":"7","author":"Frank","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol"},{"key":"10.1016\/j.prp.2025.156308_bib129","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/nano10050847","article-title":"Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities","volume":"10","author":"Deng","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib130","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mabi.201300551","article-title":"Polymer micro- and nanocapsules as biological carriers with multifunctional properties","volume":"14","author":"Musyanovych","year":"2014","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.prp.2025.156308_bib131","first-page":"292","article-title":"Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy: Development, characterisation and in-vitro cell viability study","volume":"35","author":"Kathle","year":"2018","journal-title":"J. Micro"},{"key":"10.1016\/j.prp.2025.156308_bib132","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11051-020-04990-9","article-title":"Tamoxifen-loaded PLA\/DPPE-PEG lipid-polymeric nanocapsules for inhibiting the growth of estrogen-positive human breast cancer cells through cell cycle arrest","volume":"22","author":"Behdarvand","year":"2020","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.prp.2025.156308_bib133","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.nano.2012.11.010","article-title":"Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform","volume":"9","author":"Mandal","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2025.156308_bib134","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3762\/bjnano.15.118","article-title":"Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects","volume":"15","author":"Rahat","year":"2024","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.prp.2025.156308_bib135","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.drudis.2018.05.033","article-title":"Lipid-polymer hybrid nanocarrier-mediated cancer therapeutics: current status and future directions","volume":"23","author":"Garg","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.prp.2025.156308_bib136","article-title":"A review on lipid-polymer hybrid nanocarriers in cancer","volume":"29","author":"Karati","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib137","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijbiomac.2022.05.156","article-title":"Smart active-targeting of lipid-polymer hybrid nanoparticles for therapeutic applications: Recent advances and challenges","volume":"213","author":"Khalili","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2025.156308_bib138","article-title":"Combined cancer therapeutics \u2013 Tackling the complexity of the tumor microenvironment, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol","volume":"13","author":"Roma-Rodrigues","year":"2021"},{"key":"10.1016\/j.prp.2025.156308_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114445","article-title":"Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment","volume":"188","author":"Gao","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.prp.2025.156308_bib140","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1080\/10717544.2017.1410256","article-title":"Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy","volume":"24","author":"Qi","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.prp.2025.156308_bib141","article-title":"Nanotechnology-based drug delivery systems for the improved sensitization of tamoxifen","volume":"61","author":"Chao","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib142","article-title":"Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib143","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/nano11041048","article-title":"Polymeric nanoparticle delivery of combination therapy with synergistic effects in ovarian cancer","volume":"11","author":"Levit","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib144","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.3390\/nano12152672","article-title":"Recent advances in nanoparticle-based co-delivery systems for cancer therapy","volume":"12","author":"Al Bostami","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/17425247.2011.547470","article-title":"Drug delivery systems for differential release in combination therapy","volume":"8","author":"Zhang","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.prp.2025.156308_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apsb.2025.05.039","article-title":"Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy","volume":"15","author":"Xu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.prp.2025.156308_bib147","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1021\/mp400311j","article-title":"Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity","volume":"10","author":"Jain","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib148","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2011.10.056","article-title":"Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases","volume":"422","author":"Cosco","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib149","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12249-019-1523-8","article-title":"Preparation and characterization of PLGA-PEG-PLGA nanoparticles containing salidroside and tamoxifen for breast cancer therapy","volume":"21","author":"Yu","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.prp.2025.156308_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.119126","article-title":"Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer","volume":"338","author":"Zhou","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.prp.2025.156308_bib151","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/08982104.2018.1502315","article-title":"Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment","volume":"29","author":"Jose","year":"2019","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.prp.2025.156308_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.141754","article-title":"\u03b1v\u03b23 integrin aptamer functionalized pH-responsive lipid polymer hybrid nanoparticles for targeted co-delivery of paclitaxel and tamoxifen","volume":"306","author":"Narwade","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2025.156308_bib153","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.nano.2015.12.360","article-title":"A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer","volume":"12","author":"Wang","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2025.156308_bib154","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.nano.2017.03.003","article-title":"Natural lipids enriched self-nano-emulsifying systems for effective co-delivery of tamoxifen and naringenin: systematic approach for improved breast cancer therapeutics","volume":"13","author":"Sandhu","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2025.156308_bib155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11051-023-05690-w","article-title":"Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review","volume":"25","author":"Abbasi","year":"2023","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.prp.2025.156308_bib156","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/nano13030574","article-title":"Nanoparticles: taking a unique position in medicine","volume":"13","author":"Joseph","year":"2023","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib157","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/nano10030455","article-title":"Nanopharmaceutics: Part II-production scales and clinically compliant production methods","volume":"10","author":"Souto","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.prp.2025.156308_bib158","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/pharmaceutics15112623","article-title":"Translational challenges and prospective solutions in the implementation of biomimetic delivery systems","volume":"15","author":"Wang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156308_bib159","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1021\/acs.molpharmaceut.5c00056","article-title":"Roadmap for commercial nanomedicine development: Integrating quality by design principles with pharmaceutical nanotechnology","volume":"22","author":"Maheshwari","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12951-022-01477-8","article-title":"Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists","volume":"20","author":"Joudeh","year":"2022","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.prp.2025.156308_bib161","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1039\/C5NR07161E","article-title":"Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles","volume":"8","author":"Wais","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.prp.2025.156308_bib162","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20220045","article-title":"Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials","volume":"3","author":"Lu","year":"2023","journal-title":"Exploration"},{"key":"10.1016\/j.prp.2025.156308_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01932691.2025.2496388","article-title":"Unlocking the multifaceted potential of lipid-based dispersion as a drug carrier: Targeted applications and stability improvement strategies","volume":"46","author":"Puri","year":"2025","journal-title":"J. Dispers. Sci. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib164","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1039\/D0TB00967A","article-title":"Engineering nanoparticles to tackle tumor barriers","volume":"8","author":"Li","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.prp.2025.156308_bib165","doi-asserted-by":"crossref","first-page":"35723","DOI":"10.18632\/oncotarget.26267","article-title":"Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure","volume":"9","author":"Libutti","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2025.156308_bib166","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2025.156308_bib167","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1080\/10717544.2016.1178825","article-title":"Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer","volume":"23","author":"Yuan","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.prp.2025.156308_bib168","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.taap.2016.01.005","article-title":"Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future","volume":"299","author":"Ilinskaya","year":"2016","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib169","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1513","article-title":"Nanomaterial exposure, toxicity, and impact on human health","volume":"10","author":"Pietroiusti","year":"2018","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol"},{"key":"10.1016\/j.prp.2025.156308_bib170","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1080\/17435889.2025.2533107","article-title":"Regulating nanomedicines: challenges, opportunities, and the path forward","volume":"20","author":"Mangla","year":"2025","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2025.156308_bib171","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.2174\/0929867328666210406115529","article-title":"Regulatory considerations, challenges and risk-based approach in nanomedicine development","volume":"28","author":"Cs\u00f3ka","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.prp.2025.156308_bib172","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17425255.2023.2237412","article-title":"Pharmacokinetics during therapeutic hypothermia in neonates: from pathophysiology to translational knowledge and physiologically-based pharmacokinetic (PBPK) modeling","volume":"19","author":"Leys","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.prp.2025.156308_bib173","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41568-025-00796-w","article-title":"Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer","volume":"25","author":"Harkos","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib174","doi-asserted-by":"crossref","first-page":"18319","DOI":"10.1039\/D4NR01487A","article-title":"Lipid nanoparticles for enhancing oral bioavailability","volume":"16","author":"Gangavarapu","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.prp.2025.156308_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123136","article-title":"Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation","volume":"642","author":"Rizwanullah","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114505","article-title":"Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance","volume":"161","author":"Gong","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.prp.2025.156308_bib177","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.7150\/thno.59342","article-title":"Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance","volume":"11","author":"Wei","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2025.156308_bib178","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","article-title":"Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery","volume":"18","author":"Majumder","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.prp.2025.156308_bib179","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acs.chemrev.1c00484","article-title":"Click and bioorthogonal chemistry: The future of active targeting of nanoparticles for nanomedicines?","volume":"122","author":"Taiariol","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.prp.2025.156308_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188895","article-title":"Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics","volume":"1878","author":"Saifi","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156308_bib181","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2022.1067144","article-title":"Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges","volume":"4","author":"Das","year":"2023","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.prp.2025.156308_bib182","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.colsurfb.2013.01.051","article-title":"Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer","volume":"106","author":"Majd","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2025.156308_bib183","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1039\/D2LC01177H","article-title":"3D printed microfluidics: advances in strategies, integration, and applications","volume":"23","author":"Su","year":"2023","journal-title":"Lab. Chip"},{"key":"10.1016\/j.prp.2025.156308_bib184","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3390\/cells11233868","article-title":"Translation potential and challenges of in vitro and murine models in cancer clinic","volume":"11","author":"Long","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prp.2025.156308_bib185","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.3390\/pharmaceutics14112463","article-title":"Precision nanotoxicology in drug development: current trends and challenges in safety and toxicity implications of customized multifunctional nanocarriers for drug-delivery applications","volume":"14","author":"Ahmad","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825005011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825005011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T07:36:36Z","timestamp":1765092996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825005011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":185,"alternative-id":["S0344033825005011"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156308","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in nanotechnology-based strategies to enhance tamoxifen therapy for breast cancer management","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156308"}}